Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-11-21
1999-03-02
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514573, 514912, A61K 31215
Patent
active
058772111
ABSTRACT:
The invention relates to the use of EP.sub.2 receptor agonists as neuroprotective agents. In particular said compounds are represented by the formulae: ##STR1## wherein the broken line attachment to the cyclopentane ring or the omega chain indicates the .alpha. configuration and the solid line attachment to the cyclopentane ring or the omega chain indicates the .beta. configuration, R is hydrogen or a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or --(CH.sub.2).sub.m R.sub.1 wherein m is 0-10, and R.sub.1 is an aliphatic ring having from about 3 to about 7 carbon atoms, or an aryl or heteroaryl ring having from about 4 to about 10 carbon atoms and wherein the heteroatom is selected from the group consisting of N, O and S.
REFERENCES:
patent: 4599353 (1986-07-01), Bito
patent: 4994274 (1991-02-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
Cioffi et al, Surv. of Ophthalmol, vol. 38, 107-117, May 1994, "Microvasculature of the Anterior Optic Nerve".
Matusi et al, Nippon Rinsho, vol. 52 (8), 2158-2163, Aug. 1994, "Ophthalmological Aspects of Systemic Vasculitis".
Schwartz et al, Surv. Ophthalmol., vol. 38, 23-34, May 1994, "Ciculatory Defects of the Optic Disk and Retina in Ocular Hypertension and High Pressure Open-Angle Glaucoma".
Starr et al, Exp. Eye Research, vol. 11, 170-177, 1971, "Further Studies on the Effect of Prostaglandin on Intracular Pressure in the Rabbit".
Bito et al, 231-252, 1985, Biological Protection with Prostaglandins, "Prostaglandins and Related Compounds As Potential Ocular Therapeutic Agents".
Bito et al, Applied Pharmacology in the Medical Treatment of Glaucomas 477-505. 1984, "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents".
Nilsson et al, Invest. Ophthalmol. Vis. Sci., vol. 28, 284, 1987, "PGF.sub.2.alpha. Increases Uveoscleral Outflow".
Bito et al, Arch. Ophthalmol., vol. 105, 1036-1039, Aug. 1987, "Prostaglandins, Old Concepts and New Perspectives".
Siebold et al, Prodrug 5,3, 1989, "Esterified prostaglandin shows `potent` promise".
Nials et al, ,Cardiovascular Drug Reviews, vol. 11, No. 2, 165-179, "AH13205, A Selective Prostanoid EP.sub.2 -receptor Agonist".
Coleman et al, Comprehensive Medicinal Chemistry, vol. 3, 643-714, 1990, "Prostanoids and their Receptors".
Woodward et al, Prostaglandins, 371-383, 1993, "Indentification of 19(R)-OH Prostaglandin E.sub.2 As A Selective Prostanoid EP.sub.2 -Receptor Agonist".
Chemical Abstract 123: 330038 (1995). Woodward.
Allergan
Baren Robert J.
Fay Zohreh
Hoch James M.
Voet Martin A.
LandOfFree
EP.sub.2 receptor agonists as neuroprotective agents for the eye does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EP.sub.2 receptor agonists as neuroprotective agents for the eye, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EP.sub.2 receptor agonists as neuroprotective agents for the eye will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-423374